mobile  Test Directory

NICOTINE AND METABOLITES, UR

Test Code
NICMUR
 
This test is a lab developed test. For further information, see the Compliance Remarks section below.
Synonyms
Nicotine and Metabolites, Urine, Quantitative; 3-Hydroxycotinine; Anabasine; Cotinine; Nicotine and Cotinine, LC/MS/MS, Urine; Nornicotine; Pain Management
SPECIMEN REQUIREMENTS
Container Type
Leakproof plastic urine container
Supply Item Number
1387
Specimen Type
Random urine
Preferred Volume
4 mL
Emergency Minimum Volume
1 mL
Specimen Processing
Transfer 4 mL with no additives or preservatives urine to a standard PAML aliquot tube.
Store and Transport
Refrigerated
Stability
Room Temp 1 week  Refrigerated 2 weeks  Frozen (-20 °C) 1 month  
Unacceptable Condition
Specimens exposed to more than 3 freeze/thaw cycles
Reference Laboratory
PAML
CPT Codes
80323, (HCPCS G0480)
Interface Order Code
83887.Z16
Billing Code
NICMUR
Test Schedule
Tue, Thu
Turnaround Time
1-5 days
Method
Tandem Mass Spectrometry
Reference Ranges
TitleDescriptorRangesUnits
NicotineNon-smoker< 2ng/mL
CotinineNon-smoker< 5ng/mL
3-OH-CotinineNon-smoker< 50ng/mL
NornicotineNon-smoker< 2ng/mL
AnabasineNon-smoker< 10ng/mL
> 100 ng/mL Nicotine indicates use of tobacco products and or nicotine replacement therapy.
> 200 ng/mL Cotinine indicates use of tobacco products and or nicotine replacement therapy. Cotinine is the major metabolite of nicotine.
> 50 ng/mL 3-OH-Cotinine indicates use of tobacco products and or nicotine replacement therapy. 3-OH-Cotinine is a metabolite of Cotinine.
> 30 ng/mL of Nornicotine indicates use of tobacco products and/or nicotine replacement therapy.
> 10 ng/mL Anabasine indicates use of tobacco products. Anabasine is not present in nicotine replacement therapy products such as transdermal patches, gum, nasal sprays and inhalers.
Compliance Remarks
This test was developed and its performance characteristics determined by PAML. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. PAML is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.
Notes
Useful for determination of active or passive nicotine use or for differentiation between nicotine replacement and tobacco use.

Interface Codes
typeorder codetest descriptionresult coderesult descriptionunitsdecimal placesloinc code
o83887.Z16Nicotine and Metabolites, Ur
r83887.Z16Nicotine and Metabolites, Ur83887.Z11Nicotine, Urineng/mL 3854-7
r83887.Z16Nicotine and Metabolites, Ur83887.Z12Cotinine, Urineng/mL 10366-3
r83887.Z16Nicotine and Metabolites, Ur83887.Z133-OH-Cotinine, Urine ng/mL 33916-8
r83887.Z16Nicotine and Metabolites, Ur83887.Z14Nornicotine, Urineng/mL 33917-6
r83887.Z16Nicotine and Metabolites, Ur83887.Z15Anabasine, Urineng/mL 33915-0

v1.0|1101|3|1|0


Questions/Comments